Prof Christoph Hagemeyer

Professor & Director, Monash Biomedical Imaging

Node Director, Australian National Imaging Facility (ANIF)

Node Director, Victorian Biomedical Imaging Capability (VBIC)

Principal Investigator, Monash-Helmholtz Laboratory for Radio-Immuno-Theranostics (MHELTHERA)

_

MSc, Chemistry (1997) Albert Ludwig University, Freiburg i. Br. (Germany)

PhD, Biochemistry (2001) Albert Ludwig University, Freiburg i. Br. (Germany)

_

Tel: +61 4 0921 5626

Email: christoph.hagemeyer@monash.edu

Biography

Christoph Hagemeyer is the Director of Monash Biomedical Imaging (MBI). He is also the Monash University Node Director of the Victorian Biomedical Imaging Capability, Node Director of the Australian National Imaging Facility and the Principal Investigator of the Monash-Helmholtz Laboratory for Radio-Immuno-Theranostics.

Prof Hagemeyer studied Chemistry in Germany and obtained a PhD in Biochemistry from the University of Freiburg (Germany) for contributions to the field of Cytochrome P450 metabolism in the brain. As a postdoctoral fellow, he worked in the field of Magnetic Resonance Imaging (MRI) at the “Centre national de la recherche scientifique” in Bordeaux (France) before migrating to Australia in 2005. He has particular expertise in the use of small recombinant single-chain antibodies for molecular imaging and drug delivery. He has work extensively in cardiovascular research developing anti-thrombotic fusion proteins and novel imaging probes for MRI, Ultrasound and Positron Emission Tomography.

He has published widely in leading journals (Circ Res, Adv Mater, Angew Chem..) on vascular biology, molecular imaging, recombinant antibodies, and nanotechnology. He has published over 100 papers in peer reviewed journals (currently 5,000 citations, h-index of 38). Prof Hagemeyer has attracted high-quality postgraduate students and postdoctoral fellows and has supervised over 30 postgraduate and post-doctoral students.

He has been supported throughout his career by national and international fellowships and grants. He has been awarded a total of 13 NHMRC grants, 3 ARC grants, 1 JDRF grant and 18 other grants in competitive grant applications ($20 million total received funding).

Affiliations and memberships

  • Associate Editor, Cardiovascular Therapeutics
  • Associate Editor, Frontiers Translational Pharmacology
  • Associate Editor, PLoS One
  • Associate Editor, Seminars in Thrombosis and Hemostasis
  • Board Member and Director, Australian Society for Medical Research
  • Editorial Board Member, Advanced Biosystems
  • Editorial Board Member, Frontiers in Bioengineering and Biotechnology
  • Editorial Board Member, Frontiers in Cardiovascular Medicine
  • Member, American Heart Association
  • Member, American Chemical Society
  • Member, Australian Cardiovascular Alliance
  • Member, Australian Vascular Biology Society
  • Member, Australian and New Zealand Society of Nuclear Medicine
  • Member, Australian Society of Molecular Imaging
  • Member, Australian Society for Biochemistry and Molecular Biology
  • Member, Australasian Neuroscience Society
  • Member, International Society for Heart Research
  • Member, International Society on Thrombosis and Haemostasis
  • Member, National Association of Research Fellows
  • Member, World Molecular Imaging Society